Latest Peplin news

news

09-June-09

Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more

28-May-09

Peplin's Positive Phase II AK Trial Results Published in JAAD read more

17-May-09

Positive Results for Peplin's First Phase III AK Trial read more

15-May-09

Peplin Results for the Quarter Ended 31 March 2009 read more

›› More News

About Peplin

Peplin focuses on researching, developing and commercializing innovative drugs in medical dermatology.

Peplin trades under the symbol ‘PLI’ on the Australian Securities Exchange (ASX) in the form of Chess Depository Interests (CDIs). The company is headquartered in Emeryville, California with operations in Brisbane, Queensland, Australia and a manufacturing facility in Southport, Queensland.

Our core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. The lead compound in this technology, PEP005 (ingenol mebutate), or PEP005, is in Phase III trials for the treatment of actinic keratosis (AK), sometimes known as solar keratosis or sunspots, a common pre-cancerous lesion.

Peplin retains sole rights to develop and market PEP005 and has extensive international patent coverage over its technologies.

Peplin at a glance

Offices

Emeryville, California, USA
Brisbane, Queensland, Australia

Year Founded

1998

Australian Securities Exchange Listing

September 2000

Trading symbol

ASX: PLI

US incorporation

2006 in Delaware

CEO

Tom Wiggans

Employees (global)

40 (approx)

Current development stage

Phase III

Email Us

Email: info@peplin.com